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Microglia-mediated neuroinflammatory responses are inevitable and important
pathological processes in several kinds of disorder of the central nervous system
(CNS). Therefore, alleviating activated microglia-induced inflammatory process might be
a valuable therapeutic approach to neuroinflammation-related diseases. In the present
study, we investigated BHDPC, a novel neuroprotectant discovered in our previous
study that had anti-inflammatory effects under neuroinflammatory conditions. First, we
found that BHDPC could inhibit neuroinflammatory responses and promote microglial
M2 phenotype polarization in both lipopolysaccharide (LPS)-activated BV-2 microglia
l cells. Furthermore, BHDPC provided protective actions against neuroinflammation-
induced neurotoxicity in HT22 mouse hippocampal cells co-cultured with activated BV-2
microglia. Further experiments demonstrated that BHDPC could suppress LPS-induced
activation of transcription factor nuclear factor kappa B (NF-κB) via interfering with the
degradation of the inhibitor of kappa B (IκB) and phosphorylation of IκB, the IκB kinase
(IKK). Moreover, we also found that BHDPC could induce phosphorylation of cAMP-
dependent protein kinase A (PKA) and cAMP-response element-binding protein (CREB)
in BV-2 microglial cells. Also, using the PKA-specific inhibitor, we found that BHDPC-
induced CREB phosphorylation was dependent on PKA, which also contributed to
BHDPC-mediated anti-inflammation and neuroprotection.
Keywords: BHDPC, neuroinflammation, microglia, NF-κB, CREB, PKA
Abbreviations: CNS, central nervous system; COX-2, cyclooxygenase-2; CREB, cAMP-response element-binding protein;
IL, interleukin; iNOS, inducible nitric oxide synthase; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase;
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NF-κB, nuclear factor kappa B; NO, nitric oxide; PKA,
cAMP-dependent protein kinase A; TNF, tumor necrosis factor.
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INTRODUCTION
The inflammatory response is common to the pathological
processes of various kinds of damage and disorders of the
CNS (Xanthos and Sandkuhler, 2014). Microglia are immune-
surveillance cells that also serve as major components of
inflammatory responses (Mietto et al., 2015). In response to
various microenvironmental disturbances, microglia can be
phenotypically polarized into a classical (pro-inflammatory; M1)
or an alternative (anti-inflammatory; M2) phenotype (David
and Kroner, 2011; Saijo and Glass, 2011; Joseph and Venero,
2013; Mantovani et al., 2013). Generally, activated microglial
cells can mediate neuroinflammatory responses via generating
pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-
6, and the up-regulation of iNOS/NO and prostaglandin E2
(PGE2)/COX-2 pathways, whereas M2 phenotype microglia have
been demonstrated to be associated with the expression of anti-
inflammatory M2 markers including arginase-1 (Arg-1) and
mannose receptor (CD206). Functionally, the M1 phenotype
microglia could induce or exacerbate cerebral lesions and
neuronal degeneration. In contrast, the M2 microglia confers
neuroprotection and promotes recovery and remodeling (Lu
et al., 2010; Zhou et al., 2014b). Therefore, pharmacological
inhibition of aberrant microglial activation and/or promotion of
microglial cells toward the M2 stage might be a potential regimen
for treating neuroinflammatory and neurodegenerative diseases.
The activated microglia-mediated neuroinflammatory
responses are characterized by pro-inflammatory molecule
production, which is well known to be regulated by the
transcription factor NF-κB signaling pathway (Baeuerle and
Henkel, 1994; Karin and Ben-Neriah, 2000). Normally, inactive
NF-κB proteins are bound to the IκB proteins and sequestered
in the cytosol. To induce NF-κB activation, the IKK firstly
phosphorylates and degrades IκB, which dissociates NF-κB
from complex and induces NF-κB translocation into the
nucleus. Once in the nucleus, NF-κB can interact with the
transcriptional coactivator CREB-binding protein (CBP), further
triggering transcription of various pro-inflammatory genes
including cytokines and their receptors. Activation of NF-κB
can also involve phosphorylation of several residues in the
transactivation domain of p65 subunit, among which Ser536
is well characterized (Baeuerle and Henkel, 1994; Karin and
Ben-Neriah, 2000). Suppression of NF-κB activation is an action
of many reported anti-inflammatory agents (Yuan et al., 2016; de
Oliveira et al., 2018).
cAMP-response element-binding protein is a cellular
transcription factor and is one of the best understood
phosphorylation-dependent transcription factors (Lonze
et al., 2002; Holz et al., 2006; Nguyen et al., 2007). CREB
mediates genes closely associated with neuronal survival, neural
differentiation, and neurite outgrowth (Lonze et al., 2002; Holz
et al., 2006; Nguyen et al., 2007). Several kinases have been
shown to promote phosphorylation of CREB at its transcription-
activating site, including the PKA, protein kinase C, calmodulin
kinases and pp90 ribosomal S6 kinase (Medzhitov and Horng,
2009; Ghosh et al., 2016; Park et al., 2016). Phosphorylation
of CREB promotes CREB binding to the transcriptional
coactivator CBP and formation of CREB-CBP complex, which
could suppress NF-κB-CBP complex formulation and further
block the transcription of inflammatory genes (Medzhitov and
Horng, 2009; Ghosh et al., 2016; Park et al., 2016). Moreover,
accumulating evidence also demonstrates that the CREB-CBP
complex may also induce gene expression of anti-inflammatory
cytokines in activated microglia, which are typically involved in
microglia de-activation and microglia polarization into the M2
phonotype (Ajmone-Cat et al., 2003; Ghosh et al., 2016). On the
other hand, activation of the PKA/CREB pathway could enhance
the expression of detoxifying and antioxidant enzymes, which
could protect microglial cells and neighboring neurons from
inflammation-mediated damage (Ulbrich et al., 2017).
In our previous studies, we discovered a pyrimidine
derivative, benzyl 7-(4-hydroxy-3-methoxyphenyl)-5-methyl-
4,7-dihydrotetrazolo[1,5-a] pyrimidine-6-carboxylate (BHDPC,
ChemBridge ID: 7989205; the chemical structure is shown
in Figure 1A) that can prevent chemical-induced cerebral
hemorrhage injury in docking-based virtual screening and
zebrafish models (Shen et al., 2013, 2015). In addition, we
found that BHDPC could suppress 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-induced dopaminergic neuron
loss and locomotion deficiencies in a zebrafish model of
Parkinson’s disease (PD) (Chong et al., 2015). Further studies
of brain tissue slices and SH-SY5Y cells models demonstrated
that BHDPC conferred neuroprotection via modulating
intrinsic mitochondrial apoptotic pathways, which was closely
associated with phosphorylation of PKA/CREB signaling (Chong
et al., 2015). It is well known that microglial cell activation
and sequential neuroinflammation play a critical role in
neurodegenerative disorders. Our previous studies indicated a
potential relationship between BHDPC and neuroinflammation.
Therefore, in the current study, we aimed to investigate the anti-
neuroinflammatory effects of BHDPC in LPS-stimulated BV-2
microglial cells in vitro and a LPS-induced mouse model in vivo.
Moreover, the role of BHDPC in the NF-κB and PKA/CREB
pathways was further investigated. Finally, the protective effects
of BHDPC against neuroinflammation-induced neurotoxicity in
HT22 mouse hippocampal cells co-cultured with BV-2 microglia
were also explored.
MATERIALS AND METHODS
Chemicals and Reagents
BHDPC was purchased from ChemBridge Corporation
(ChemBridge ID: 7989205, San Diego, CA, United States). LPS
(Escherichia coli serotype 055: B5) was purchased from Sigma-
Aldrich (St. Louis, MO, United States). PKA-specific inhibitor
(H-89) was purchased from Selleck Chemicals (Shanghai, China).
All other chemicals and solvents were of molecular biology grade.
Cell Culture and Treatment
BV-2 cells, previously characterized as a widely used
immortalized murine microglial cell line (Blasi et al., 1990;
Saleppico et al., 1996), were obtained from the Kunming
Cell Bank of Type Culture Collection, Kunming Institute of
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FIGURE 1 | (A) Chemical structure of BHDPC and its effects on the cell
viability of BV-2 microglial cells. BV-2 microglial cells were treated with BHDPC
with or without incubation of lipopolysaccharide (LPS) (500 ng/mL) for for
24 h. (B) Effects of BHDPC alone on the cell viability. (C) Effects of BHDPC on
the cell viability with LPS stimulation. Data are presented as means ± SEM of
three independent experiments in triplicate. Control group was untreated cells.
#P < 0.05 and ##P < 0.01, versus control group; ∗P < 0.05 and ∗∗P < 0.01,
versus LPS-treated group.
Zoology. HT22 mouse hippocampal cells were obtained from the
University of California. BV-2 cells and HT22 cells were cultured
in RPMI 1640 and DMEM, respectively (Gibco, Carlsbad,
CA, United States). The medium was supplemented with 10%
FBS (Gibco), 100 U/ml penicillin (Gibco), and 100 µg/ml
streptomycin. Cells were cultured in an atmosphere of 95% air
and 5% CO2 at 37◦C. LPS stock (10 µg/ml) and BHDPC stock
(50 mM) were firstly prepared in PBS and DMSO, respectively,
and then diluted into final doses.
BV-2 Microglia and HT22 Mouse
Hippocampal Cells Co-culture System
Neuroprotective effects of BHDPC were tested in a BV-2
microglia cell and HT22 mouse hippocampal cell co-culture
system using Corning
R©
Transwell
R©
polycarbonate membrane cell
inserts (12 mm Transwell with 0.4 µm pore size insert; Corning,
New York, NY, United States). HT22 cells were cultured in a 24-
well plate, and BV-2 cells were seeded on the Transwell insert
that was then placed above the HT22 neuronal cells layer for co-
culture. At 24 h after cell seeding, BV-2 cells were pretreated with
various doses of BHDPC for 1 h and then co-stimulated with LPS
(500 ng/ml) for another 24 h. After that, HT22 cells were then
subjected to further assay.
Cell Viability Assay
Cell viability was measured by the MTT assay. Briefly, cells
were seeded in 24- or 96-well culture plates and received the
indicated treatments. After that, cells were incubated with MTT
and finally the absorbance at 570 nm was measured using a
Flexstation 3 Microplate Reader (Molecular Devices, Sunnyvale,
CA, United States).
NO Assay and ROS Measurement
Microglial production of NO was assessed by measuring the
accumulated nitrite released into culture media. Briefly, after the
indicated treatment, culture media was collected and analyzed
via a Nitric Oxide Colorimetric Assay kit according to the
manufacturer’s protocol (BioVision, Milpitas, CA, United States).
The level of ROS was analyzed using the fluorescent probe, CM-
H2DCFDA (Molecular Probes, Eugene, OR, United States). Once
treatment was finished, cells were collected, washed with PBS
and incubated with the probe. After that, the ROS level was also
measured using a Flexstation 3 Microplate Reader.
Enzyme-Linked Immunosorbent Assay
(ELISA) for TNF-α, IL-6, IL-1β, IL-10, and
PGE2
The TNF-α, IL-6, IL-10, IL-1β, and PGE2 released in conditioned
media were assessed by specific ELISA Ready-SET-Go kits
(eBiosciences, San Diego, CA, United States). The levels were
quantified following the manufacturer’s protocols.
Mitochondrial Membrane Potential
Measurement
After treatment, the cells were incubated with JC-1 (10 µg/mL)
at 37◦C for 15 min and then washed with PBS. For signal
quantification, the intensity of red fluorescence and green
fluorescence was determined. The ratio of JC-1 red/green
fluorescence intensity was semi-quantitatively calculated and the
value was normalized to the LPS-treated group.
Cellular DNA Fragmentation Assay and
Caspase 3 Activity Assay
The effect of BHDPC on activated microglial-induced cellular
DNA fragmentation in HT22 cells was measured using a
Cellular DNA Fragmentation ELISA kit (Roche Applied Science,
Mannheim, Germany) according to the protocols. Absorbance
at 450 nm was measured and represented as the level of
DNA fragmentation. The activity of caspase 3 was measured
using the commercially available EnzChek Caspase-3 Assay Kit
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(Invitrogen, San Diego, CA, United States) according to the
manufacturer’s protocol.
Electrophoretic Mobility Shift Assay
(EMSA)
The nuclear protein was separated using the Nuclear and
Cytoplasmic Protein Extraction Kit (P0028, Beyotime, Shanghai,
China). The DNA binding activities of NF-κB was analyzed using
an ELISA-based TransAM NF-κB p65 EMSA kit (ActiveMotif,
Carlsbad, CA, United States) according to the manufacturer’s
protocol. Briefly, binding buffer and nuclear extract (∼30 µg)
were added to the assay plate. Then, the plate was incubated for
1 h at room temperature in the dark, followed by incubation with
NF-κB p65 antibody (1:1000; 1 h). Absorbance at 450 nm was
measured via microplate reader.
Reporter Gene Luciferase Assays
Briefly, BV-2 cells were transfected using the pNFκB-luc reporter
plasmid provided by the Cignal NFκB Reporter (luc) Kit (CCS-
013L, SABiosciences, Frederick, MD, United States) using the
Attractene Transfection Reagent (QIAGEN, Hilden, Germany)
according to manufactrurer’s protocol. Transfection efficiency
was controlled by co-transfection with Renilla luciferase reporter
plasmid. About 24 h after transfection, the transfected cells
received the indicated treatment. The samples were then
subjected to the Dual-Luciferase
R©
Reporter Assay System (E1910;
Promega, Madison, WI, United States), and luciferase activities
were measured.
Quantitative PCR (qPCR) Assay
Total RNA of BV-2 cells and brain samples was extracted using
the High Pure RNA Isolation Kit (Roche Applied Science)
according to the manufacturer’s protocol. Isolated RNA was
then reverse-transcribed into cDNA using the Transcriptor First
Strand cDNA Synthesis Kit (Roche Applied Science) following
the standard protocol. The qPCR assay was conducted using
FastStart Universal SYBR Green Master reagents (Roche Applied
Science) with the Applied Biosystems 7900 HT Fast Real-
Time PCR System (Applied Biosystems Inc., Foster City, CA,
United States). The amplification parameters used here was 50◦C
for 2 min then 95◦C for 10 min, followed by 40 cycles of
95◦C for 15 s and 60◦C for 30 s. Each sample was analyzed in
triplicate and the relative expression of mRNA was calculated
after normalization to GAPDH. The primer sequences used were
also listed (Table 1).
Immunohistochemistry
For BV-2 microglia cells staining, cells were washed, fixed by
3.7% PFA, permeabilized by 0.3% Triton X-100-PBS for 15 min,
and then blocked for another 30 min at room temperature.
After that, cells were incubated with rabbit anti-NF-kB p65
(1:500) overnight at 4◦C and goat anti-rabbit, Alex Fluor
594 conjugate secondary antibody (111-585-003, 1:500, Jackson
Immuno Research Laboratories, West Grove, PA, United States)
for 1 h at room temperature in the dark. For the nuclei
observation, the cells were further stained with DAPI solution
TABLE 1 | Primers used in qPCR assay.
Gene Forward primer (5′→3′) Reverse primer (5′→3′)
iNOS CAAGAGTTTGACCAGAGGACC TGGAACCACTCGTACTTGGGA
COX-2 TTGAAGACCAGGAGTACAGC GGTACAGTTCCATGACATCG
TNF-α CCTATGTCTCAGCCTCTTCT CCTGGTATGAGATAGCAAAT
IL-1β GGCAACTGTTCCTGAACTCAACTG CCATTGAGGTGGAGAGCTTT
CAGC
IL-6 CCACTTCACAAGTCGGAGGCTT CCAGCTTATCTGTTAGGAGA
CD206 CTTCGGGCCTTTGGAATA AT TAGAAGAGCCCTTGGGTTGA
Arg-1 GTGAAGAACCCACGGTCTGT GCCAGAGATGCTTCCAACTG
YM1/2 CAGGGTAATGAGTGGGTTGG CACGGCACCTCCTAAATTGT
GAPDH ATGTACGTAGCCATCCAGGC AGGAAGGAAGGCTGGAAGAG
(Thermo Scientific) for 10 min. Finally, the samples were
mounted with the Prolong anti-fade reagent and imaged by the
Leica TCS SP8 confocal laser scanning microscope system (Leica,
Wetzlar, Germany).
Preparation of Whole Cell, Cytoplasmic,
and Nuclear Protein
For the whole cell protein extraction, BV-2 cells and mouse
brain samples were washed with ice-cold PBS and incubated
with RIPA lysis buffer (Beyotime). Cell lysates were centrifuged,
and the supernatant was collected and stored. The subcellular
fractionation was prepared using the Nuclear and Cytoplasmic
Extraction Reagents (Thermo Scientific) according to the
manufacturer’s f nuclear extraction kit protocol. The protein
content was assayed using the BCA protein quantification kit
(Thermo Scientific).
Co-immunoprecipitation Assays
The immunoprecipitation was conducted using the PierceTM
Protein A/G Magnetic Beads kit (Thermo Scientific) according to
the protocols. In brief, cell protein extraction was performed and
protein concentration quantified. Then, each protein extraction
(∼500 µg) was mixed with immunoprecipitation antibody (CBP
primary antibody, 5 µg). The mixture was incubated overnight
at 4◦C. After that, 25 µg of magnetic beads were added and
incubated for 1 h at room temperature. Beads were then washed
and antigen was eluted. For blots, 20 µl of target antigen in
elution buffer was used and detected as described in the Western
blot analysis.
Western Blot
Aliquots protein samples (30∼40 µg) were resolved by
SDS-PAGE (7.5–15%) and transferred to PVDF membranes.
Membranes were blocked, followed by incubation at 4◦C
overnight with diluted primary antibodies: CBP (1:1000), p-IκBα
(1:1000), IκBα (1:1000), p-IKKα/β (1:1000), IKKα (1:1500),
p-PKA (1:1000), PKA (1:2000), p-CREB (1:1000), CREB (1:1500),
p-NF-κB p65 (1:1000), NF-κB p65 (1:1000), β-actin (1:2000),
β-Tubulin (1:2000), and GAPDH (1:2000) purchased from
Cell Signaling Technology (Beverly, MA, United States); iNOS
(1:500), COX-2 (1:1000), and IBA1 (1:1500) were purchased
from Invitrogen. Membranes were washed and incubated with
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HRP-linked, anti-rabbit/mouse secondary antibody (1:2500,
Cell Signaling Technology) for 1 h at room temperature.
Finally, bands were visualized using an ECL plus Western
Blotting Detection Reagents kit (GE Healthcare, Milwaukee, WI,
United States). The membranes were then scanned on a Bio-Rad
ChemiDoc XRS Imaging System, and the intensity of the protein
bands was analyzed using Bio-Rad Quantity One Software (Bio-
Rad, Hercules, CA, United States).
Graphing and Statistical Analysis
Statistical analyses were performed using GraphPad Prism (ver.
6.0, GraphPad Inc., San Diego, CA, United States), and data
were represented as the mean ± standard deviation (SD). The
difference between two groups was compared by using an
independent sample t-test and one- or two-way ANOVA with
Bonferroni’s correction for multiple group comparison. Pearson’s
correlation coefficient was used for the correlation analyses.
P< 0.05 was considered significant.
RESULTS
Effects of BHDPC on the Cell Viability of
BV-2 Microglial Cells
In order to estimate the range of effective concentrations, we
firstly detected the action of BHDPC on the cell viability of BV-2
cells. As shown in Figure 1B, subsequent determination indicated
that BHDPC (0.3–30 µM) had no cytotoxic action on BV-2 cells
with 24 h incubation (all p> 0.01, versus the control group). LPS
(500 ng/mL) treatment for 24 h slightly decreased the cell viability
to 96.12 ± 3.46%, with no significant difference compared to the
control group (Figure 1C, p > 0.05, versus the control group).
Furthermore, pretreatment with BHDPC (1–10 µM) was able to
restore the decreased cell viability of BV-2 cells stimulated by LPS
for 24 h (Figure 1C, p> 0.05, versus the LPS-treated group).
BHDPC Suppressed the Expression of
NO/iNOS and PGE2/COX-2, and the
Production of Pro-inflammatory
Cytokines in LPS-Activated BV-2
Microglial Cells
We initially evaluated the effects of BHDPC on NO and
PGE2 production and expression of iNOS and COX-2 in LPS-
stimulated BV-2 cells. As illustrated in Figures 2A,D, production
of NO and PGE2 was markedly increased by LPS (all p < 0.01,
versus the control group). However, pretreatment with BHDPC
(1, 3, and 10 µM) for 1 h markedly decreased LPS-induced
NO and PGE2 increases in a concentration-dependent manner
(Figures 2A,D, all p< 0.05, versus the LPS-treated group). Then,
as shown in Figures 2B,E, LPS-induced expression of iNOS and
COX-2 was significantly inhibited by BHDPC treatment (1, 3,
FIGURE 2 | BHDPC blocked the NO/iNOS and PGE2/COX-2 pathways in LPS-activated BV-2 microglial cells. Cells were treated with BHDPC for 1 h, followed by
LPS stimulation. The cytokine level was determined by Elisa. The mRNA and protein expression were determined by qPCR and Western blot assay, respectively.
(A,D) BHDPC inhibited the production of NO (A) and PGE2 (D). (B,E) BHDPC suppressed the expression of iNOS (B) and COX-2 (E). (C,F) BHDPC decreased the
mRNA expression of iNOS (C) and COX-2 (F). The mRNA level was normalized to GAPDH and expressed as fold- increase. Data are presented as means ± SEM of
three independent experiments in triplicate. Control group was untreated cells. #P < 0.05 and ##P < 0.01, versus control group; ∗P < 0.05 and ∗∗P < 0.01, versus
LPS-treated group.
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and 10 µM) in a concentration-dependent manner (all p < 0.05
versus the LPS-treated group). The best inhibitory effect was
found at the dose of 10 µM, evidenced by the highest inhibition
of NO, iNOS, PGE2, and COX-2 production (all p < 0.05 versus
the LPS-treated group). Correspondingly, pretreatment with 1,
3, and 10 µM BHDPC dose-dependently decreased the mRNA
expression of iNOS and COX-2 in LPS-activated BV-2 microglia
(Figures 2C,F, all p< 0.05 versus the LPS-treated group).
Consecutively, we investigated the effects of BHDPC on pro-
inflammatory cytokines in LPS-activated BV-2 microglial cells.
LPS stimulation significantly increased the production of TNF-
α (Figure 3A), IL-6 (Figure 3B), and IL-1β (Figure 3C) in BV-2
cells, when compared to the control group (all p< 0.01, versus the
control group). However, LPS-induced increased levels of TNF-
α, IL-6, and IL-1β were significantly suppressed by pretreatment
with BHDPC (1–10 µM) for 1 h in a dose-dependent fashion.
Moreover, BHDPC (1–10 µM) also dose-dependently decreased
the mRNA expression of TNF-α, IL-6, and IL-1β (Figures 3D–F,
all p < 0.05 versus the LPS-treated group). Pretreatment with
10 µM BHDPC decreased the levels of TNF-α, IL-6, and IL-1β
to 60.7%, 55.12%, and 54.5% of those of the LPS-treated group,
respectively (all p< 0.01, versus the LPS-treated group).
BHDPC Promoted Microglial Polarization
Toward the M2 Anti-inflammatory
Phenotype in LPS-Stimulated BV-2
Microglial Cells
Firstly, BHDPC (1, 3, and 10 µM) increased the expression of
IL-10 (Figure 4A), CD206 (Figure 4B), and Arg-1(Figure 4C)
in LPS-stimulated BV-2 cells (all p < 0.01 versus the LPS-treated
group). Interestingly, we found that treatment with BHDPC at a
dose of 3 µM had the best effect on M2 marker induction, which
increased the level of IL-10, CD206, and Arg-1 to∼1.6,∼2.6, and
∼2.9-fold that of the control group, respectively (all p< 0.01). In
addition, LPS stimulation decreased mRNA expression of YM1/2,
CD206, and Arg-1(Figures 4D–F), whereas BHDPC incubation
significantly reversed this tendency. As expected, 3 µM BHDPC
had the best potency, and increased the level of YM1/2, CD206
and Arg-1 to∼2.3,∼2.4, and∼2.5-fold that of the control group
in LPS-stimulated BV-2 microglial cells (both p< 0.01).
BHDPC Prevented LPS-Activated BV-2
Microglia-Mediated Neurotoxicity in
HT22 Hippocampal Cells
Since BHDPC showed inhibitory effects on neuroinflammation
in LPS-activated microglia, we then investigated whether
BHDPC could prevent neuroinflammation-mediated neuronal
death using the BV-2 microglia and HT22 cells co-culture
system. As shown in Figures 5A,B, LPS stimulation induced a
significant reduction in the cell viability of co-cultured HT22
cells (p < 0.01, versus the control group). Pre-treatment with
BHDPC (1, 3, and 10 µM) significantly prevented HT22 cells
against activated microglia-induced cytotoxicity, and increased
the cell viability to ∼156.2, ∼177.5, and ∼204.3% of that
of the LPS-treated group, respectively, in a dose-dependent
manner (all p < 0.01). Moreover, we also found that LPS
stimulation significantly increased intracellular ROS production
in HT22 neurons (Figure 5C). However, the LPS-induced
FIGURE 3 | BHDPC suppressed the production of pro-inflammatory cytokines in LPS-activated BV-2 microglial cells. Cells were treated with BHDPC for 1 h,
followed by LPS stimulation. The cytokine level was determined by Elisa. The mRNA and protein expression were determined by qPCR and Western blot assay,
respectively. (A–C) BHDPC inhibited the production of TNF-α, IL-6, and IL-1β. (D–F) BHDPC decreased the mRNA expression of TNF-α, IL-6, and IL-1β. The mRNA
level was normalized to GAPDH and expressed as fold- increase. Data are presented as means ± SEM of three independent experiments in triplicate. Control group
was untreated cells. #P < 0.05 and ##P < 0.01, versus control group; ∗P < 0.05 and ∗∗P < 0.01, versus LPS-treated group.
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FIGURE 4 | BHDPC promoted microglia polarization to the M2 phenotype in LPS-stimulated BV-2 microglial cells. Cells were treated with BHDPC for 1 h, followed
by LPS stimulation. The cytokine level was determined by Elisa. The mRNA and protein expression were determined by qPCR and Western blot assay, respectively.
(A–C) BHDPC increased M2 marker IL-10, CD206, and Arg-1 expression in BV-2 cells. (D–F) BHDPC prevented the LPS-induced down-regulation of YM1/2,
CD206, and Arg-1 in mRNA level. The mRNA level was normalized to GAPDH and expressed as fold- increase. Data are presented as means ± SEM of three
independent experiments in triplicate. Control group was untreated cells. #P < 0.05 and ##P < 0.01, versus control group; ∗P < 0.05 and ∗∗P < 0.01, versus
LPS-treated group.
ROS production was blocked by BHDPC (1, 3, and 10 µM)
treatment in a dose-dependent fashion (p < 0.01, versus the
LPS-treated group). As shown in Figure 5D, further results on
HT22 cells caspase 3 activity also showed that LPS stimulation
significantly increased caspase 3 activity to ∼ 454.3% that
of the control group, whereas BHDPC (1, 3, and 10 µM)
incubation resulted in significant reduction of caspase 3 activity,
in a dose-dependent manner (all p < 0.01). In addition, the
results of DNA fragmentation also indicated that BHDPC (1,
3, and 10 µM) incubation could protect against cell damage,
as evidenced by significant reductions in DNA fragmentation
to ∼79.2, ∼70.1, and ∼56.4% that of the LPS-treated group,
respectively (Figure 5E, all p < 0.01). In addition, JC-1 dye
was used to monitor the mitochondrial membrane potential
(MMP); as illustrated in Figures 5F,G, LPS stimulation induced
significant MMP dissipation. However, BHDPC at 1, 3, and
10 µM attenuated LPS-activated BV-2-induced MMP loss in a
concentration-dependent manner (all p< 0.01).
BHDPC Inhibited the Activation of NF-κB
Pathway in LPS-Activated BV-2
Microglial Cells and LPS-Challenged
Mouse Brains
To explore the role of BHDPC in NF-κB activation, the NF-κB
luciferase reporter system was used to determine NFκB-regulated
gene transcription and signal transduction. Results indicated that
BHDPC (1, 3, and 10 µM) could inhibit the NF-κB-driven gene
transcriptional activity increased by LPS stimulation in a dose-
dependent fashion (Figure 6A, all p < 0.01 versus LPS-treated
group).
Next, we examined the effects of BHDPC on nuclear
translocation of the NF-κB p65 subunit. As shown in Figure 6B,
BHDPC (1, 3, and 10 µM) significantly blocked the NF-
κB p65 LPS-activated nuclear translocation (Figure 6C,
p < 0.01). The nuclear translocation was further revealed by
immunofluorescence assay. As expected, BHDPC (10 µM)
pretreatment significantly reduced the LPS-stimulated
accumulation of NF-κB p65 in the nuclei (Figure 6D).
Further, we found that BHDPC significantly reduced the
NF-κB p65 phosphorylation induced by LPS (Figure 6E,
all p < 0.01). Corroboratively, the ELISA-based EMSA was
conducted to assess the binding of NF-κB to DNA, and the
results showed that BHDPC (1, 3, and 10 µM) significantly
abolished the LPS-induced NF-κB-DNA binding activity in a
dose-dependent manner (Figure 6F, p< 0.01). Moreover, the co-
immunoprecipitation results indicated that the formation of the
NF-κB and coactivator CBP complex detected in LPS-induced
BV-2 cells (Figure 6G) was reversed by BHDPC treatment.
In LPS-activated BV-2 microglial cells, we found that the
levels of phosphorylated IKKα/β and IκBα were markedly
increased (Figures 7A,B p < 0.01 versus the control). However,
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FIGURE 5 | BHDPC provided neuroprotective effects against the HT22 cells damages induced by LPS-activated BV-2 microglia. BV-2 cells were co-cultured on
Transwell inserts with HT22 cells. Microglial were pretreated with BHDPC for 1 h, and then stimulated with LPS. (A) The cell viability was measured via MTT assay.
(B) Cellular morphology of HT22 cells. (C,D) The cellular ROS level and caspase 3 activity were measured via the fluorogenic probe and Caspase-3 Assay Kit,
respectively. (E) Cell DNA fragmentation was measured via ELISA assay. (F,G) The mitochondrial membrane potential (MMP) was detected using JC-1 dye. Data are
presented as means ± SEM of three independent experiments in triplicate. Control group was untreated cells. #P < 0.05 and ##P < 0.01, versus control group;
∗P < 0.05 and ∗∗P < 0.01, versus LPS-treated group.
BHDPC significantly attenuated the increase in phosphorylation
of IKKα/β and IκBα in a dose-dependent manner. Notably,
10 µM BHDPC reduced the levels of phosphorylated IKKα/β
and IκBα to ∼18.7%, and 17.7% of those of the LPS-treated
group, respectively. In addition, LPS decreased IκBα degradation
in BV-2 cells, which was reversed by BHDPC (1, 3, and 10 µM)
(Figure 7B, p< 0.01).
BHDPC Promoted PKA/CREB
Phosphorylation in LPS-Activated BV-2
Microglial Cells and LPS-Challenged
Mice Brains
Encouraged by the elevated phosphorylation of PKA/CREB
mediated by BHDPC in SH-SY5Y cell lines in our previous
study, here we further assessed the intracellular cAMP level
and phosphorylation of PKA and CREB in BV-2 microglial
cells. Firstly, we found that BHDPC dose-dependently promoted
CREB and PKA phosphorylation (Figures 8A,B, all p < 0.01
versus the control group) in BV-2 microglia cell without LPS
stimulation. Further results also indicated that BHDPC (1, 3, and
10 µM) significantly reversed the LPS-induced reduction of PKA
phosphorylation (Figure 8C, all p < 0.01). In addition, BHDPC
significantly reversed the decrease of CREB phosphorylation
induced by LPS in a dose-dependent fashion (Figure 8D, all
p < 0.01 versus the LPS-treated group), whereas this effect
was abolished by pretreatment with the PKA inhibitor, H89.
Furthermore, co-immunoprecipitation of CREB with CBP from
BHDPC-treated BV-2 cells indicated that BHDPC promoted
formulation of the CREB-CBP complex (Figure 8E).
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FIGURE 6 | BHDPC inhibited NF-κB activation in LPS-stimulated BV-2 microglial cells. (A) BHDPC suppressed the NF-κB reporter luciferase activity in
LPS-activated BV-2 cells. Transfected cells were pretreated with BHDPC for 1 h, and then stimulated with/without LPS. The luciferase activity was measured and
then expressed as fold-increase. (B–D) BHDPC suppressed NF-κB p65 translocation in LPS-activated BV-2 cells. The whole cell, cytoplasmic, and nuclear protein
were prepared and the levels of cytoplasmic p65 (B) and nuclear p65 (C) were measured using Western Blot. (D) The NF-κB p65 protein localization was also
detected via immunofluorescence staining. The NF-κB p65 proteins were labeled by p65 primary antibody and Alexa Fluor 594-conjugated secondary antibody. The
nucleus was counterstained with DAPI. (E) The level of phosphorylation p65 phosphorylation were measured using Western Blot. (F) StA inhibited DNA binding of
NF-κB in LPS-stimulated BV-2 microglia. Nuclear extracts were prepared and subjected to the ELISA-based DNA binding assay. The absorbance was measured
using a microplate reader. (G) BHDPC inhibited LPS-induced formulation of NF-κB and coactivator CBP complex, as detected via the co-immunoprecipitation. Data
are presented as means ± SEM of three independent experiments in triplicate. Control group was untreated cells. #P < 0.05 and ##P < 0.01, versus control group;
∗P < 0.05 and ∗∗P < 0.01, versus LPS-treated group.
Blocking the PKA Pathway Reversed
BHDPC-Mediated Anti-
neuroinflammatory and
Neuroprotective Actions
We next used the PKA inhibitor, H89 to block the PKA
activity in BV-2 microglial cells, to test whether BHDPC-
mediated inhibitory effects against neuroinflammation were
mediated by PKA. We found that H89 significantly abolished the
BHDPC-mediated inhibition of production of pro-inflammatory
mediators and cytokines, including NO (Figure 9A), PEG2
(Figure 9B), and TNF-α (Figure 9C) (all p< 0.01). Furthermore,
we found that blocking the PKA activity also abrogated the
effect of BHDPC on promoting M2 marker protein expression,
as evidenced by the levels of IL-10, CD206, and Arg-1 being
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FIGURE 7 | BHDPC inhibited LPS-induced IKK α/β phosphorylation, IκB α phosphorylation, and IκB α degradation in activated BV-2 microglial cells. Cells were
treated with BHDPC for 1 h, followed by LPS stimulation. After incubation, protein was prepared and the levels of (A) total/phosphorylated IκB α and
total/phosphorylated IKK α/β (B) were measured via Western Blot. Data are presented as the mean ± SD of three independent experiments (n = 9). Data are
presented as means ± SEM of three independent experiments in triplicate. Control group was untreated cells. #P < 0.05 and ##P < 0.01, versus control group;
∗P < 0.05 and ∗∗P < 0.01, versus LPS-treated group.
decreased when compared to that of the group only incubated
with BHDPC but not H89 (Figures 9D–F). Interestingly, we
also found that PKA inhibitor suppressed the inhibitory effects
of BHDPC on NF-κB activation. H89 aborted the inhibitory
effect of BHDPC on NF-κB-driven gene transcriptional activity
(Figure 9G) and p65 nucleus translocation (Figure 9H). Also,
the suppressive action on the formation of the NF-κB and
CBP complex was abolished by PKA inhibitor (Figure 9I).
Moreover, PKA inhibitor H89 also abolished the BHDPC-
mediated neuroprotective actions in HT22 cells. As shown
in Figure 9J, H89 treatment reversed the BHDPC-mediated
increase of cell viability of HT22 cells in the co-culture system
(p < 0.01). Moreover, PKA inhibition by H89 also abrogated
BHDPC-mediated inhibition of caspase 3 activity of HT22 cells
in the co-culture system (Figure 9K, p < 0.01). Further results
on the DNA fragmentation of HT22 cells also showed that
PKA inhibitor abolished the protective effects of BHDPC against
LPS-activated BV-2 microglia-induced HT22 cell damage, as
evidenced by the significant increase in DNA fragmentation
compared to the group without H89 incubation (Figure 9L,
p< 0.01).
DISCUSSION
Neuroinflammatory responses are inevitable and important
pathological processes in several kinds of CNS disorder (Xanthos
and Sandkuhler, 2014; Mietto et al., 2015). Microglia are
immune-surveillance cells and serve as major components
of inflammation. (Xanthos and Sandkuhler, 2014; Chuang
et al., 2015; Mietto et al., 2015). Therefore, alleviating activated
microglia-induced inflammatory processes and subsequent
cellular damage might be a valuable therapeutic approach
for neuroinflammation-related diseases (Gemma, 2010;
Dhama et al., 2015). In this study, we showed for the
first time that the novel neuroprotectant, BHDPC could
inhibit neuroinflammatory responses in LPS-activated BV-2
microglia cells. Moreover, BHDPC provided protection against
neuroinflammation-induced neurotoxicity in HT22 mouse
hippocampal cells. Furthermore, the results demonstrated that
the effects of BHDPC were mediated by the inactivation of
NF-κB and activation of PKA/CREB signaling.
It is well known that the NO/iNOS and PGE2/COX-2
signal pathways are significantly up-regulated in LPS-activated
BV-2 microglial cells. iNOS and COX-2 are associated with
neuronal inflammation and subsequent pathogenesis of CNS
diseases (Minghetti and Levi, 1998). Therefore, agents that
could regulate levels of iNOS and COX-2 might be able
to prevent and treat neuroinflammation-related disorders
(David and Kroner, 2011; Saijo and Glass, 2011; Joseph and
Venero, 2013; Mantovani et al., 2013; Kwon et al., 2017).
In this study, we firstly found that BHDPC could suppress
both NO/iNOS and PGE2/COX-2 signaling pathways in
LPS-activated BV-2 microglial cells. Next, we found that
BHDPC could also decrease the expression of pro-inflammatory
cytokines. These pro-inflammatory cytokines could promote
neuronal damage, and also induce more microglia activation
as a feedback mechanism (Block et al., 2007). Therefore,
modulating cytokine function is one mechanisms by which
to control inflammation-induced CNS disorders (Minghetti
and Levi, 1998; Block et al., 2007). Hence, the current data
demonstrated that BHDPC was able to attenuate aberrant
microglial activation and activated the microglia-induced
inflammatory response.
Similar to macrophages, microglial cells also show plasticity,
and polarize into different functional phenotypes. In response
to various microenvironmental disturbances, microglia can
be phenotypically polarized into classical (pro-inflammatory;
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FIGURE 8 | BHDPC induced the phosphorylation of PKA and CREB and formation of CREB-CBP complex in BV-2 microglial cells. Cells were firstly incubated with
H89 for 30 min and treated with BHDPC for 1 h, after that treated with or without LPS. (A,B) BHDPC induced phosphorylation of PKA and CREB in BV-2 cells
without LPS stimulation. (C,D) BHDPC promoted phosphorylation of PKA and CREB in LPS-activated BV-2 microglial cells. (E) BHDPC induced the formation of
CREB and coactivator CBP complex detected via the co-immunoprecipitation. Data are presented as means ± SEM of three independent experiments in triplicate.
Control group was untreated cells. #P < 0.05 and ##P < 0.01, versus control group; ∗P < 0.05 and ∗∗P < 0.01, versus LPS-treated group.
M1) and alternative (anti-inflammatory; M2) phenotypes
(Lu et al., 2010; Zhou et al., 2014b). It is well known that the
anti-inflammatory M2 phenotype confers neuroprotective
effects via enhancing the expression of cytokines and proteins
involved in inflammatory resolution, homeostasis, and wound-
healing (David and Kroner, 2011; Saijo and Glass, 2011;
Joseph and Venero, 2013; Mantovani et al., 2013). Inhibiting
the M1 phenotype while stimulating the M2 phenotype
has been suggested as a more viable potential strategy for
the treatment of neuroinflammatory disorders (Hu et al.,
2015). For instance, two agents approved for multiple
sclerosis (Freigang et al., 2011) therapy, glatiramer acetate
and β-interferon, have demonstrated not only M1-inhibiting
actions, but also promote a balance between M1 and M2
cells (Burger et al., 2009; Kieseier, 2011). Our current results
indicated that BHDPC could significantly promote microglial
polarization toward the anti-inflammatory M2 phenotype in
LPS-stimulated BV-2 microglial cells. Taken together, results
suggest that BHDPC could promote microglial M2 phenotype
polarization, which might contribute to BHDPC-induced
neuroinflammation.
Microglia-mediated neuroinflammation is characterized
by pro-inflammatory molecule production, these molecules
are neurotoxic and subsequently result in death and damage
of neighboring neurons (Chan et al., 2017; Chen et al.,
2017; Alcalde-Estevez et al., 2018). Therefore, agents that
are able to block pro-inflammatory mediators would be
expected to confer neuroprotection. The neuron-microglia
co-culture system provides an environment for both microglia
and neurons to grow together in close proximity; hence, it
is widely used to test the neuroprotective effects of anti-
inflammatory compounds. In this study, we also used HT22
hippocampal neurons and the BV-2 microglia co-culture
system to further explore BHDPC-mediated actions against
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FIGURE 9 | Blocking the PKA pathway reversed BHDPC-mediated anti-neuroinflammatory and neuroprotective actions. BV-2 cells were pretreated with 10 µM
BHDPC or 5 µM H89 for 1 h, and then exposed to LPS. PKA inhibitor H89 reversed BHDPC-mediated inhibition of NO (A), PGE2 (B), and TNF-α expression (C).
(D–F) PKA inhibition abrogated BHDPC-induced expression of IL-10 (D), CD206 (E), and Arg-1 (F). PKA inhibitor reversed the inhibitory actions of BHDPC on
NF-κB reporter luciferase activity (G), p65 translocation (H), and formulation of NF-κB and CBP complex (I). Cells were pretreated with BHDPC or H89 for 1 h, and
then exposed to LPS for 24 h. PKA inhibitor reversed the protective actions of BHDPC on cell viability (J), cell caspase-3 activity (K), and DNA fragmentation (L).
Data are presented as means ± SEM of three independent experiments in triplicate. Control group was untreated cells. #P < 0.05 and ## P < 0.01, versus control
group; ∗P < 0.05 and ∗∗P < 0.01, versus LPS-treated group.
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inflammation-induced neurotoxicity. The BV-2 microglia
were cultured in a transwell system that was placed above the
HT-22 neuronal layer. The conditioned media from LPS-
stimulated microglia was diffused into the HT-22 neuronal
cells, resulting the HT-22 neurons death and apoptosis.
Firstly, we confirmed that BHDPC could significantly alleviate
LPS-stimulated microglia-induced cell toxicity in HT-22
cells. Furthermore, BHDPC was able to block the excess
intracellular ROS level of HT-22 stimulated by activated
microglia. Intracellular ROS served as an important second
messenger that can activate a cascade of harmful events
resulting in neuronal cell death and damage (Zhou et al.,
2014a; Jiang et al., 2015). It is well known that loss of MMP
is a hallmark of early-stage apoptosis and caspase 3 activation
plays a key role in the execution phase of apoptosis. In
this study, we also found that BHDPC could supress not
only MMP loss, but also caspase 3 activation in co-culture
HT-22 cells. These observations were further confirmed in
experiments showing that BHDPC prevented inflammation-
induced DNA fragmentation in HT22 cells. Taknen together,
the current results clearly demonstrate the inhibitory
actions of BHDPC against neuroinflammation-induced cell
apoptosis.
The NF-κB signaling pathway is well known to be a central
regulator of several kinds of inflammatory responses, including
microglial-mediated neuroinflammation (Baeuerle and Henkel,
1994; Karin and Ben-Neriah, 2000). Since we found that BHDPC
could abate pro-inflammatory responses, investigation of the NF-
κB pathway might help us to further explain the underlying
mechanisms. Firstly, the inhibitory activity of BHDPC against
NF-κB transduction was confirmed in this study (Iu et al., 2017;
Khan et al., 2017). Next, BHDPC-induced suppression of NF-
κB p65 phosphorylation was also found in LPS-stimulated BV-2
microglia. Furthermore, BHDPC inhibited nuclear translocation
of NF-κB in LPS-treated BV-2 microglia. Moreover, BHDPC
abated NF-κB-DNA binding activity and the interaction of NF-
κB with CBP. All of these results demonstrated that BHDPC
could suppress NF-κB activation in BV-2 cells. Furthermore, we
then tested the action of BHDPC in regulating IKK and IκB,
two important upstream modulators of NF-κB signal pathways
(Baeuerle and Henkel, 1994; Karin and Ben-Neriah, 2000; Baima
et al., 2010). We found that BHDPC could block not only
phosphorylation of IKK and IκB, but also degradation of IκB
in LPS-activated microglia. Taken together, these data sugges
that BHDPC could inhibit NF-κB activation, which might
be associated with BHDPC-mediated anti-neuroinflammatory
actions.
In our previous study, we found that BHDPC could activate
PKA/CREB signaling in neuroblastoma SH-SY5Y cells. Similarly,
in this study, we also found that BHDPC obviously induced
the phosphorylation of PKA and CREB in both microglial cells
and mouse brain. Notably, the BHDPC-induced phosphorylation
of CREB was abolished by PKA inhibitor H89 in BV-2
microglia, which further indicated that the BHDPC-mediated
CREB activation was also dependent on PKA activation. Once
CREB becomes phosphorylated at Ser133, it can interact
with CBP and induce the expression of anti-inflammatory
cytokine genes, among which IL-10, IL-4, and IL-13 are the
most important for reducing inflammation. Here, we also
demonstrated that BHDPC promoted the CREB-CBP complex
in LPS-stimulated microglial cells. These results were consistent
with previous findings showing that BHDPC increased the
expression of IL-10 and other M2 markers in LPS-activated
microglia. Moreover, promoting the formation of the CREB-
CBP complex could also result in the displacement of NF-κB
from CBP and block NF-κB-CBP complex formulation, which
inhibited expression of a variety of pro-inflammatory genes
whose transcriptions are positively regulated by the NF-κB
signaling pathway (Medzhitov and Horng, 2009; Ghosh et al.,
2016; Park et al., 2016). Encouraged by the effect of BHDPC
on PKA/CREB phosphorylation, we next assessed the role of
PKA activation by BHDPC in LPS-induced neuroinflammation.
Firstly, we observed that PKA inhibition using PKA inhibitor
H89 obviously abolished the inhibitory effects of BHDPC on the
production of inflammatory mediators and cytokines, including
NO, PGE2, and TNF-α in LPS-stimulated BV-2 microglia
cells. Moreover, BHDPC-mediated promotion of microglial M2
phenotype polarization was also blocked by PKA inhibitor.
Interestingly, the BHDPC-induced NF-κB inactivation was also
abrogated in condition of PKA inhibiton. Previous studies also
indicacted that PKA activation could supress the activation
of NF-κB in microglia, but PKA inhibitor or gene slicnece
could revised PKA activator-mediated NF-κB incativation. Our
results indicated that BHDPC might be a potent PKA activator,
but further details need to be exploredin the following study.
Furthermore, we also demonstrated PKA inhibition by a specific
inhibitor also abolished the inhibitory actions of BHDPC against
neuroinflammation-induced cell death and apoptosis. Therefore,
we suggest that PKA-dependent CREB phosphorylation induced
by BHDPC contributes to BHDPC-mediated anti-inflammation
and neuroprotection.
In summary, our study demonstrated several principal
findings, as follows: (1) BHDPC could inhibit neuroinflammatory
response in LPS activated BV-2 microglia cells; (2) BHDPC
provided protective actions against neuroinflammation-
induced neurotoxicity in hippocampal cells; (3) BHDPC
conferred anti-inflammatory and neuroprotective effects
via the inactivation of NF-κB and activation of PKA/CREB
signaling.
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